StockData

Ascentage Pharma Group International vs Protagonist Therapeutics

AAPG and PTGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AAPG and PTGX compare

Protagonist Therapeutics grew revenue faster over the last twelve months (34.8% versus −41.5% for Ascentage Pharma Group International).

Protagonist Therapeutics keeps more of each dollar of sales as profit, with a net margin of 29.4% compared with −216% at Ascentage Pharma Group International.

Protagonist Therapeutics scores higher on the StockData Score (12 against 3 for Ascentage Pharma Group International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAAPGPTGX
Size and price
Market cap–$8.1B
Share price$13.14$124.67
Change, 1 year−61.7%47.3%
Change, 5 years–275%
Beta (5Y)1.430.59
Employees767132
StockData Score
Total score312 (better)
Valuation score00
Growth score12 (better)
Performance score14 (better)
Health score16 (better)
Dividend score00
Valuation
P/E–121×
P/S–28.6×
P/B–9.6×
EV/EBITDA–122×
P/FCF–61.8×
FCF yield–1.6%
Fair value–$41.72
Margin of safety–−199%
Growth
Revenue growth (TTM)−41.5%34.8% (better)
Revenue growth, 5Y average–10.0%
Net income growth (TTM)–59.3%
EPS growth (TTM)–47.1%
Profitability
Gross margin91.5%–
Operating margin–20.7%
Net margin−216%29.4% (better)
FCF margin−209%46.3% (better)
Return on equity−156%11.0% (better)
Return on invested capital–73.3%
Financial health
Debt / equity1.50 (better)0.00
Current ratio1.7921.71 (better)
Altman Z-score–111.10
Piotroski F-score–5
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.00%117%
Held by insiders13.0%1.7%
Insider net buying, 12 months–−$95.0M
Superinvestors holding–1
Short interest, % of float–16.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.